PSMAfore: A phase III Open-label Multi-Center Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Na ve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
